文献速递淋巴瘤

惰性非霍奇金淋巴瘤或套细胞淋巴瘤一线苯达莫司汀联合利妥昔单抗对比R-CHOP或R-CVP:BRIGHT 5年随访研究结果

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
PubMed 文献 · J Clin Oncol · 2019-02-27

BRIGHT研究比较苯达莫司汀联合利妥昔单抗(BR)与R-CHOP或R-CVP一线治疗初治惰性非霍奇金淋巴瘤或套细胞淋巴瘤的疗效与安全性。5年随访显示BR组5年无进展生存率为65.5%,R-CHOP/R-CVP组为55.8%,风险比为0.61(95%CI 0.45-0.85,P=0.0025),BR在长期疾病控制上更优,但总生存无显著差异,且BR组继发恶性肿瘤更多。

要点

  • BR组5年无进展生存率为65.5%,R-CHOP/R-CVP组为55.8%,风险比0.61(95%CI 0.45-0.85;P=0.0025)。
  • 无进展生存、无事件生存和缓解持续时间均支持BR优于R-CHOP/R-CVP,但总生存无显著差异。
  • BR组继发恶性肿瘤数量高于R-CHOP/R-CVP组,长期随访未收集到新的安全性数据。

核心结论

  • BR在长期疾病控制方面优于R-CHOP/R-CVP,应考虑作为惰性和套细胞淋巴瘤患者的一线治疗选择。

研究设计与样本

  • BRIGHT研究(ClinicalTrials.gov标识符:NCT00877006)为比较BR与R-CHOP或R-CVP一线治疗初治惰性非霍奇金淋巴瘤或套细胞淋巴瘤患者的疗效与安全性研究,本研究提供长期随访数据。

主要发现

  • 研究完成时BR组和R-CHOP/R-CVP组的所有时间-事件终点中位值均未达到。
  • 5年无进展生存率:BR组为65.5%,R-CHOP/R-CVP组为55.8%;差异被认为显著,风险比为0.61(95%CI 0.45-0.85;P=0.0025)。
  • 无事件生存的风险比(P=0.0020)和缓解持续时间的风险比(P=0.0134)也支持BR方案优于R-CHOP/R-CVP。
  • 总生存方面未观察到显著差异。
  • BR、R-CHOP和R-CVP的总体安全性特征与预期一致;长期随访期间未收集到新的安全性数据。

关键数值与推荐

  • 5年无进展生存率:BR组65.5% vs R-CHOP/R-CVP组55.8%。
  • 无进展生存的风险比:0.61(95%CI 0.45-0.85;P=0.0025),BR组低于R-CHOP/R-CVP组。
  • 无事件生存的风险比P=0.0020,缓解持续时间的风险比P=0.0134,均支持BR优于R-CHOP/R-CVP。
  • 总生存无显著差异。

临床怎么用

  • 作者认为,BR在长期疾病控制方面优于R-CHOP/R-CVP,应考虑作为惰性和套细胞淋巴瘤患者的一线治疗选择。

局限性

  • 长期随访期间未收集到新的安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data. PATIENTS AND METHODS: Patients were monitored for a minimum of 5 years after completion of study treatment for the time-to-event end points of progression-free survival (PFS), event-free survival, duration of response, and overall survival per investigator assessment. Data on the number of patients who received second-line anticancer treatment and the occurrence of other malignancies were also collected. RESULTS: The medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment group and 55.8% in the R-CHOP/R-CVP group. The difference in PFS was considered significant with a hazard ratio of 0.61 (95% CI, 0.45 to 0.85; P = .0025). The hazard ratio for event-free survival and duration of response (P = .0020 and .0134, respectively) also favored the BR regimen over R-CHOP/R-CVP. However, no significant difference in overall survival was observed. The overall safety profiles of BR, R-CHOP, and R-CVP were as expected; no new safety data were collected during long-term follow-up. A higher number of secondary malignancies was noted in the BR treatment group. CONCLUSION: Overall, BR demonstrated better long-term disease control than R-CHOP/R-CVP and should be considered as a first-line treatment option for patients with indolent and mantle-cell lymphoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol. 2019. PMID: 30811293. doi:10.1200/JCO.18.00605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。